Fri Sep 20 06:33:12 UTC 2024: ## Alzheimer’s Breakthrough or False Hope? New Drugs Spark Controversy
Two new drugs, lecanemab (Leqembi) and donanemab (Kisunla), have become the center of a heated debate in the medical world. These drugs, the first capable of slowing the progression of Alzheimer’s disease, are hailed by some as a major breakthrough, while others see them as another costly disappointment.
The drugs, developed by Biogen/Eisai and Eli Lilly respectively, have shown a 30% reduction in cognitive decline in patients at the early stages of the disease. While this may seem significant, critics argue the benefits are marginal and overshadowed by the risks of side effects like brain swelling and bleeding, which can be fatal in rare cases. Additionally, the drugs are incredibly expensive, with lecanemab alone costing an estimated €133 billion for all eligible patients in the EU.
Despite the controversy, the US has approved both drugs. The EU, however, rejected lecanemab and remains hesitant about donanemab. The UK has taken a middle ground, approving lecanemab but not making it available on the National Health Service.
Proponents of the drugs, including many neurologists, believe they can provide precious months of autonomy for patients and that their effectiveness could increase if administered earlier in the disease’s progression. However, critics fear the drugs could create false hope and leave poorer patients behind, with wealthier individuals seeking treatment in countries like the US.
The debate is further fueled by past failures of Alzheimer’s treatments that targeted amyloid plaques, the protein clumps found in the brains of patients. While lecanemab and donanemab are the first successful drugs targeting these plaques, the skepticism remains due to past overpromises and accusations of conflicts of interest between pharmaceutical companies, researchers, and patient advocacy groups.
Some experts suggest that while the new drugs are a step forward, a focus on other mechanisms behind Alzheimer’s is essential. They acknowledge that the disease’s complexity means single-target treatments are unlikely to achieve a significant impact. Nevertheless, they emphasize the critical role of these drugs in the ongoing fight against this debilitating disease.
First Piper 